301 related articles for article (PubMed ID: 30790200)
1. First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing.
Zaborenko N; Shi Z; Corredor CC; Smith-Goettler BM; Zhang L; Hermans A; Neu CM; Alam MA; Cohen MJ; Lu X; Xiong L; Zacour BM
AAPS J; 2019 Feb; 21(3):32. PubMed ID: 30790200
[TBL] [Abstract][Full Text] [Related]
2. Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report.
Suarez-Sharp S; Cohen M; Kesisoglou F; Abend A; Marroum P; Delvadia P; Kotzagiorgis E; Li M; Nordmark A; Bandi N; Sjögren E; Babiskin A; Heimbach T; Kijima S; Mandula H; Raines K; Seo P; Zhang X
AAPS J; 2018 Aug; 20(6):93. PubMed ID: 30151612
[TBL] [Abstract][Full Text] [Related]
3. Approaches for Establishing Clinically Relevant Dissolution Specifications for Immediate Release Solid Oral Dosage Forms.
Hermans A; Abend AM; Kesisoglou F; Flanagan T; Cohen MJ; Diaz DA; Mao Y; Zhang L; Webster GK; Lin Y; Hahn DA; Coutant CA; Grady H
AAPS J; 2017 Nov; 19(6):1537-1549. PubMed ID: 28831727
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Dissolution Profiles From Process Parameters, Formulation, and Spectroscopic Measurements.
Zhao Y; Li W; Shi Z; Drennen JK; Anderson CA
J Pharm Sci; 2019 Jun; 108(6):2119-2127. PubMed ID: 30742835
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
[TBL] [Abstract][Full Text] [Related]
6. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
[TBL] [Abstract][Full Text] [Related]
7. Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
Heimbach T; Suarez-Sharp S; Kakhi M; Holmstock N; Olivares-Morales A; Pepin X; Sjögren E; Tsakalozou E; Seo P; Li M; Zhang X; Lin HP; Montague T; Mitra A; Morris D; Patel N; Kesisoglou F
AAPS J; 2019 Feb; 21(2):29. PubMed ID: 30746576
[TBL] [Abstract][Full Text] [Related]
8. Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report.
Abend A; Heimbach T; Cohen M; Kesisoglou F; Pepin X; Suarez-Sharp S
AAPS J; 2018 Apr; 20(3):60. PubMed ID: 29633092
[TBL] [Abstract][Full Text] [Related]
9. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
[TBL] [Abstract][Full Text] [Related]
10. Dissolution Testing in Drug Product Development: Workshop Summary Report.
Abend A; Curran D; Kuiper J; Lu X; Li H; Hermans A; Kotwal P; Diaz DA; Cohen MJ; Zhang L; Stippler E; Drazer G; Lin Y; Raines K; Yu L; Coutant CA; Grady H; Krämer J; Pope-Miksinski S; Suarez-Sharp S
AAPS J; 2019 Jan; 21(2):21. PubMed ID: 30690680
[TBL] [Abstract][Full Text] [Related]
11. Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models.
Uebbing L; Klumpp L; Webster GK; Löbenberg R
Drug Des Devel Ther; 2017; 11():1163-1174. PubMed ID: 28442890
[TBL] [Abstract][Full Text] [Related]
12. Integrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example Ibuprofen.
Cristofoletti R; Hens B; Patel N; Esteban VV; Schmidt S; Dressman J
J Pharm Sci; 2019 Dec; 108(12):3842-3847. PubMed ID: 31539541
[TBL] [Abstract][Full Text] [Related]
13. Review of real-time release testing of pharmaceutical tablets: State-of-the art, challenges and future perspective.
Markl D; Warman M; Dumarey M; Bergman EL; Folestad S; Shi Z; Manley LF; Goodwin DJ; Zeitler JA
Int J Pharm; 2020 May; 582():119353. PubMed ID: 32325242
[TBL] [Abstract][Full Text] [Related]
14. Application of artificial neural networks for Process Analytical Technology-based dissolution testing.
Nagy B; Petra D; Galata DL; Démuth B; Borbás E; Marosi G; Nagy ZK; Farkas A
Int J Pharm; 2019 Aug; 567():118464. PubMed ID: 31252145
[TBL] [Abstract][Full Text] [Related]
15. A novel in vivo predictive dissolution testing coupled with a modeling and simulation for hydrogel matrix monolithic extended release oral dosage forms.
Kambayashi A; Dressman JB
Eur J Pharm Sci; 2019 Oct; 138():105044. PubMed ID: 31421255
[TBL] [Abstract][Full Text] [Related]
16. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
17. In vitro monitoring of dissolution of an immediate release tablet by focused beam reflectance measurement.
Coutant CA; Skibic MJ; Doddridge GD; Kemp CA; Sperry DC
Mol Pharm; 2010 Oct; 7(5):1508-15. PubMed ID: 20715796
[TBL] [Abstract][Full Text] [Related]
18. Near infrared spectroscopy to monitor drug release in-situ during dissolution tests.
Sarraguça MC; Matias R; Figueiredo R; Ribeiro PR; Martins AT; Lopes JA
Int J Pharm; 2016 Nov; 513(1-2):1-7. PubMed ID: 27601336
[TBL] [Abstract][Full Text] [Related]
19. An IQ Consortium Perspective on Connecting Dissolution Methods to In Vivo Performance: Analysis of an Industrial Database and Case Studies to Propose a Workflow.
Aburub A; Chen Y; Chung J; Gao P; Good D; Hansmann S; Hawley M; Heimbach T; Hingle M; Kesisoglou F; Li R; Rose J; Tisaert C
AAPS J; 2022 Mar; 24(3):49. PubMed ID: 35348922
[TBL] [Abstract][Full Text] [Related]
20. FIP Guidelines for Dissolution Testing of Solid Oral Products.
Friedel HD; Brown CK; Barker AR; Buhse LF; Keitel S; Kraemer J; Morris JM; Reppas C; Sperry DC; Sakai-Kato K; Stickelmeyer MP; Shah VP
J Pharm Sci; 2018 Dec; 107(12):2995-3002. PubMed ID: 30148985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
